Prognostic factors for successful conversion from cyclosporine to FK 506-based immunosuppressive therapy for refractory rejection after liver transplantation. US Multicenter FK 506 Liver Study Group.
Klintmalm
G B
GB
Baylor University Medical Center, Dallas, Texas.
Goldstein
R
R
Gonwa
T
T
Wiesner
R H
RH
Krom
R A
RA
Shaw
B W
BW
Stratta
R
R
Ascher
N L
NL
Roberts
J W
JW
Lake
J
J
D000208:Acute Disease; D000367:Age Factors; D000704:Analysis of Variance; D002908:Chronic Disease; D016572:Cyclosporine / Q000627:therapeutic use*; D004351:Drug Resistance; D005260:Female; D006084:Graft Rejection / Q000517:prevention & control*; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D008111:Liver Function Tests; D016031:Liver Transplantation / Q000276:immunology* / Q000502:physiology; D008297:Male; D015999:Multivariate Analysis; D011379:Prognosis; D012727:Sex Characteristics; D016019:Survival Analysis; D016559:Tacrolimus / Q000009:adverse effects / Q000097:blood / Q000627:therapeutic use*
D007166:Immunosuppressive Agents; D016572:Cyclosporine; D016559:Tacrolimus